These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16684030)

  • 1. Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
    Ram R; Van Wagoner DR
    J Cardiovasc Electrophysiol; 2006 May; 17(5):542-3. PubMed ID: 16684030
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
    Shroff SC; Ryu K; Martovitz NL; Hoit BD; Stambler BS
    J Cardiovasc Electrophysiol; 2006 May; 17(5):534-41. PubMed ID: 16684029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure.
    Kimura M; Ogawa H; Wakeyama T; Takaki A; Iwami T; Hadano Y; Mochizuki M; Hiratsuka A; Shimizu A; Matsuzaki M
    J Cardiol; 2011 Mar; 57(2):208-14. PubMed ID: 21185153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
    Laszlo R; Bentz K; Konior A; Eick C; Schreiner B; Kettering K; Schreieck J
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Oct; 382(4):347-56. PubMed ID: 20799026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
    Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
    Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
    J Cardiovasc Electrophysiol; 2014 May; 25(5):556-577. PubMed ID: 24612029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
    Yang SS; Han W; Zhou HY; Dong G; Wang BC; Huo H; Wei N; Cao Y; Zhou G; Xiu CH; Li WM
    Chin Med J (Engl); 2008 Jan; 121(1):38-42. PubMed ID: 18208664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone blockade and heart failure.
    Jessup M
    N Engl J Med; 2003 Apr; 348(14):1380-2. PubMed ID: 12668698
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
    Stambler BS; Laurita KR; Shroff SC; Hoeker G; Martovitz NL
    Heart Rhythm; 2009 Jun; 6(6):776-83. PubMed ID: 19427273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
    Esposito CT; Varahan S; Jeyaraj D; Lu Y; Stambler BS
    J Cardiovasc Electrophysiol; 2013 Jul; 24(7):806-12. PubMed ID: 23489714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists for heart failure.
    Richards AM
    Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
    MMW Fortschr Med; 2005 Jul; 147(27-28):44. PubMed ID: 16041942
    [No Abstract]   [Full Text] [Related]  

  • 16. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure: the role for mineralocorticoid receptor antagonists.
    Pitt B
    Swiss Med Wkly; 2014; 144():w13959. PubMed ID: 24845362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.